Erste Group raises Eli Lilly stock rating to Buy, sees strong sales
Erste Group analysts upgraded Eli Lilly stock from Hold to Buy, citing a robust product demand and a promising pipeline of potential successes. The analysts highlighted the pharmaceutical company's ...
clinicaltrialsarena16h
Lilly’s investigational Alzheimer’s to be investigated in prevention trial
The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...
Lilly Needs a Plan to Spur Weight-Loss Drug Sales, Investors Say
Lilly Chief Financial Officer Lucas Montarce told Reuters last month the drugmaker is trying to balance its demand-generation activities with its ability to supply more patients. The company last year ...
How Eli Lilly is approaching GLP-1 marketing and what’s next
Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...
What Analysts Think of Eli Lilly Stock Ahead of Earnings
Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.
Taiwan News1d
Europe Biopharmaceuticals Market Behaviors Unveiled Ethnography’s Lens into Consumer Insights
Request To Download Free Sample of This Strategic Report @ Highlighted with 43 tables and 86 figures, this 160-page report ?Europe Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service ...
Taiwan News1d
Global Biopharmaceuticals Market Depth of Insights Ethnography’s Contribution to Consumer Behavior
Request To Download Free Sample of This Strategic Report @ Highlighted with 78 tables and 119 figures, this 215-page report ?Global Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...
PharmiWeb1d
Peptide Therapeutics Market to Surpass USD 117.4 Billion by 2034 at a 10.8% of CAGR, Driven by Demand for Targeted Treatments
Peptide Therapeutics MarketThe global peptide therapeutics market is set for remarkable expansion, with its valuation projected to grow from USD 42.1 billion in 2024 to USD 117.4 billion by 2034. The ...
DelveInsight Business Research, LLP: Competitive Intelligence in Breast Cancer: Tracking the Evolving HR+ HER2-ve Breast Cancer Landscape
A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor the evolving breast cancer competitive intelligence ...
Competitive Intelligence in Breast Cancer: Tracking the Evolving HR+ HER2-ve Breast Cancer Landscape
HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone ...
clinicaltrialsarena2d
Pharma companies will continue to push for diversity, experts say
Experts believe that pharma will continue as normal due to the scientific justification of running diverse clinical trials.
Why Eli Lilly and Company (LLY) Is the Best Cancer Stock to Buy According to Hedge Funds
Eli Lilly & Co. (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. Its products span oncology, ...